<DOC>
	<DOCNO>NCT01104714</DOCNO>
	<brief_summary>The purpose study determine correlation tumor response 3 dos chemotherapy induction use Docetaxel , Cisplatine 5-Fluorouracile advance stage epidermoid carcinoma upper aero digestive tract presence one combination 3 genetic polymorphism and/or 5 intra-tumoral transcriptional modification .</brief_summary>
	<brief_title>Pharmacogenetic Response Chemotherapy Induction ORL Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Hypopharyngeal Neoplasms</mesh_term>
	<criteria>Squamous cell carcinoma originate mouth , oropharynx , larynx hypopharynx histologically document . The disease one follow UICC 2002 stage , regardless ganglion status : T3 MO T4 MO Treatment via chemotherapy , radiotherapy surgery ( except diagnostic biopsy ) start The pluridisciplinary committee rule surgical option technical functional reason Absence distant metastasis OMS general health status 0 2 Patient give informed consent Patient affiliate social security system Undifferentiated squamous cell carcinoma nasopharynx ( UCNT ) Another cancer priorly treat one follow chemotherapy : Docetaxel , Cisplatin , 5Fluorouracile Creatininemia &gt; 2 mg/dl and/or creatinine clearance &lt; 60ml/min Patient guardianship Presence another severe pathology include : severe chronic cardiac , renal and/or hepatic insufficiency severe medullary hypoplasia severe autoimmune disease psychosis senility</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>